A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer.

被引：14
|
作者：
Isakoff, S. J. [1 ]
Overmoyer, B. [1 ]
Tung, N. M. [1 ]
Gelman, R. S. [1 ]
Habin, K. [1 ]
Qian, J. [1 ]
Giranda, V. [1 ]
Shepherd, S. [1 ]
Garber, J. E. [1 ]
Ellisen, L. W. [1 ]
Winer, E. P. [1 ]
Goss, P. E. [1 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P3-16-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-16-05
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I study of PARP inhibitor ABT-888 and carboplatin with novel imaging in metastatic breast cancer (MBC) (NCI-8609)
    Ramaswamy, Bhuvaneswari
    Lustberg, Maryam B.
    Wesolowski, Robert
    Layman, Rachel M.
    Mrozek, Ewa
    Olson, Erin M.
    Andreopoulou, Eleni
    Garcia-Villa, Alejandra
    Chalmers, Jeff
    Cotrill, Jeffrey A.
    Nutter, Julie
    Ledin, Jamie
    Schaaf, Larry J.
    Bajestani, Saeed
    Zhao, Weiqiang
    Geyer, Susan
    Chen, Alice
    Shapiro, Charles L.
    Villalona-Calero, Miguel A.
    Knopp, Michael
    Grever, Michael R.
    CANCER RESEARCH, 2012, 72
  • [32] Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer
    Hobbs, Evthokia A.
    Litton, Jennifer K.
    Yap, Timothy A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (14) : 1825 - 1837
  • [33] Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
    Chiorean, E. Gabriela
    Guthrie, Katherine A.
    Philip, Philip A.
    Swisher, Elizabeth M.
    Jalikis, Florencia
    Pishvaian, Michael J.
    Berlin, Jordan
    Noel, Marcus S.
    Suga, Jennifer M.
    Garrido-Laguna, Ignacio
    Cardin, Dana Backlund
    Radke, Marc R.
    Duong, Mai
    Bellasea, Shay
    Lowy, Andrew M.
    Hochster, Howard S.
    CLINICAL CANCER RESEARCH, 2021, 27 (23) : 6314 - 6322
  • [34] Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer and BRCA1/2 mutations
    Keenan, Tanya
    Liu, David
    Elmarakeby, Haitham
    Stover, Daniel
    Kochupurakkal, Bose
    Tracy, Adam
    Danielczyk, Elaine
    Anderson, Leilani
    Andrews, Chelsea
    Reardon, Brendan
    Overmoyer, Beth
    Winer, Eric
    Zheleva, Daniella
    Chiao, Judy
    Blake, David
    Van Allen, Eliezer
    Shapiro, Geoffrey I.
    Tolaney, Sara
    CANCER RESEARCH, 2019, 79 (13)
  • [35] Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer
    Tutt, A.
    Robson, M.
    Garber, J. E.
    Domchek, S.
    Audeh, M. W.
    Weitzel, J. N.
    Friedlander, M.
    Carmichael, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [36] A phase I/II study of the PARP inhibitor, ABT-888 plus 5-fluorouracil and oxaliplatin (modified FOLFOX-6) in patients with metastatic pancreatic cancer.
    Pishvaian, M. J.
    Slack, R.
    Witkiewicz, A.
    He, A. R.
    Hwang, J. J.
    Hankin, A.
    Ley, L.
    Apte, S. K.
    Littman, S. J.
    Weiner, L. M.
    Marshall, J.
    Brody, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer identified by cell-free DNA or tumor tissue genotyping
    Vidula, Neelima
    Damodaran, Senthil
    Blouch, Erica L.
    Horick, Nora
    Ruffle-Deignan, Nathan Royce
    Bhave, Manali
    Shah, Ami N.
    Varella, Leticia
    Abramson, Vandana
    Sparano, Joseph
    Ellisen, Leif
    Alim, Ishraq
    Ostrer, Harry
    Rugo, Hope
    Bardia, Aditya
    CANCER RESEARCH, 2023, 83 (05)
  • [38] Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer.
    Drew, Y.
    Ledermann, J. A.
    Jones, A.
    Hall, G.
    Jayson, G. C.
    Highley, M.
    Rea, D.
    Glasspool, R. M.
    Halford, S. E. R.
    Crosswell, G.
    Colebrook, S.
    Boddy, A. V.
    Curtin, N. J.
    Plummer, E. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)
    Monica K. Malhotra
    Shalu Pahuja
    Brian F. Kiesel
    Leonard J. Appleman
    Fei Ding
    Yan Lin
    Hussein A. Tawbi
    Ronald G. Stoller
    James J. Lee
    Chandra P. Belani
    Alice P. Chen
    Vincent L. Giranda
    Stacie Peacock Shepherd
    Leisha A. Emens
    S. Percy Ivy
    Edward Chu
    Jan H. Beumer
    Shannon Puhalla
    Breast Cancer Research and Treatment, 2023, 198 : 487 - 498
  • [40] Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib
    McCann, Kelly E.
    FUTURE ONCOLOGY, 2019, 15 (15) : 1707 - 1715
12345